The litigation, spearheaded by the firm Levi & Korsinsky, highlights a series of disclosures regarding the company’s financial health and production timelines. Plaintiffs claim that Microvast maintained optimistic gross-margin targets and Huzhou Phase 3.2 completion dates despite internal issues that were allegedly known to the firm. These included significant delays in customer rollouts and production timing problems.
The scrutiny intensified following a sharp market reaction on March 17, 2026, when Microvast shares plummeted 34.2% to close at $1.52. That drop followed a quarterly report revealing revenue of $96.5 million—well below the $136.4 million consensus—alongside a 1.0% gross margin and a $32.5 million impairment charge for specialized ESS components. Joseph E. Levi, lead counsel for the plaintiffs, argued that generic risk warnings cannot shield a company from failing to disclose specific operational hurdles that directly impact share value.





Comments (0)
No comments yet. Be the first!